Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings/Collaborations In Brief: Andrx/Watson Pharmaceuticals

Executive Summary

Andrx/Watson Pharmaceuticals: Enter definitive agreement whereby Watson will purchase an additional $15.5 mil. of Fort Lauderdale-based Andrx common stock, representing approximately 13% of the common shares outstanding. With the new investment, Watson now controls 19.5% of the controlled-release drug firm Andrx. Circa, which recently merged into Watson, had bought shares of Andrx in July 1994. Andrx and Watson will become 50/50 partners in the ANCIRC joint venture formed in July 1994 and have committed to adding two new generic products to the ANCIRC pipeline, Andrx says...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027140

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel